WVNews | Business
Phase 3 ARCHES Trial Shows XTANDI (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate...
West Virginia Business
•
Feb 11, 2019
